T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
C.H. Robinson
CHRW
$17.5B
| $14.8M | ﹤0.01% |
167,595
+6,281
| +4% | +$501K |
|
1027
Lennox International
LII
$14.5B
| $14.7M | ﹤0.01% |
27,424
+9,950
| +57% | +$4.9M |
|
|
NARI
1028
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $14.6M | ﹤0.01% |
304,033
-69,314
| -19% | -$3.07M |
|
1029
Centrus Energy
LEU
$3.83B
| $14.5M | ﹤0.01% |
340,038
+1,788
| +0.5% | +$79.1K |
|
1030
Cars.com
CARS
$672M
| $14.3M | ﹤0.01% |
727,988
+683,975
| +1,554% | +$12.5M |
|
1031
Kyndryl
KD
$3.04B
| $14.1M | ﹤0.01% |
536,967
+407,264
| +314% | +$9.76M |
|
1032
F5
FFIV
$23.6B
| $14.1M | ﹤0.01% |
81,906
+1,614
| +2% | +$282K |
|
1033
Doximity
DOCS
$4.74B
| $14.1M | ﹤0.01% |
503,744
-56,082
| -10% | -$1.48M |
|
1034
SLM Corp
SLM
$5.22B
| $14M | ﹤0.01% |
674,107
-142,167
| -17% | -$2.99M |
|
1035
Owens Corning
OC
$12.3B
| $13.9M | ﹤0.01% |
80,259
+5,789
| +8% | +$1M |
|
1036
Maplebear
CART
$11.6B
| $13.8M | ﹤0.01% |
430,773
-3,522,843
| -89% | -$121M |
|
1037
Enpro
NPO
$7.12B
| $13.8M | ﹤0.01% |
95,093
+79,687
| +517% | +$12.1M |
|
1038
Evolent Health
EVH
$527M
| $13.8M | ﹤0.01% |
722,959
+5,625
| +0.8% | +$144K |
|
1039
Invesco Senior Loan ETF
BKLN
$6.76B
| $13.8M | ﹤0.01% |
656,100
| – | – |
|
1040
Selective Insurance
SIGI
$5.59B
| $13.8M | ﹤0.01% |
147,063
-299,496
| -67% | -$29.3M |
|
|
FOLD
1041
DELISTED
Amicus Therapeutics
FOLD
| $13.8M | ﹤0.01% |
1,390,047
+686
| +0% | +$7.04K |
|
1042
iShares Core MSCI EAFE ETF
IEFA
$196B
| $13.8M | ﹤0.01% |
189,741
-69,926
| -27% | -$5.15M |
|
|
VRNA
1043
DELISTED
Verona Pharma
VRNA
| $13.7M | ﹤0.01% |
+949,375
| New | +$13.9M |
|
1044
Corbus Pharmaceuticals
CRBP
$195M
| $13.7M | ﹤0.01% |
302,186
+109,691
| +57% | +$4.61M |
|
1045
Incyte
INCY
$24.4B
| $13.6M | ﹤0.01% |
225,112
-418,544
| -65% | -$23.7M |
|
1046
First Citizens BancShares
FCNCA
$25.6B
| $13.6M | ﹤0.01% |
8,085
-684
| -8% | -$1.14M |
|
1047
Allogene Therapeutics
ALLO
$683M
| $13.5M | ﹤0.01% |
5,790,542
+1,612,923
| +39% | +$4.76M |
|
1048
Essent Group
ESNT
$6.23B
| $13.3M | ﹤0.01% |
237,440
+60,313
| +34% | +$3.36M |
|
1049
Tapestry
TPR
$25.9B
| $13.3M | ﹤0.01% |
310,787
+6,013
| +2% | +$251K |
|
1050
Markel Group
MKL
$22.8B
| $13.2M | ﹤0.01% |
8,382
+46
| +0.6% | +$71.4K |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.